Hypertension
Conditions
Keywords
Isometric exercise, Exercise, Hypertension, High blood pressure, General practice, Feasibility study
Brief summary
High blood pressure affects many people in the United Kingdom. People with raised blood pressure (140-159/90-99 mmHg) are recommended to make changes in their lifestyle (e.g. smoking/alcohol/diet/exercise) and/or medication in order to reduce their blood pressure. Current knowledge suggests that a particular type of exercise - isometric exercise - can lower blood pressure. Isometric exercise involves holding a fixed body position for a short period of time. As most of the information about the benefits of this type of exercise comes from laboratory-based studies, researchers want to find out if it is possible for GP practices to offer NHS patients with clinically high blood pressure an isometric exercise plan to do at home and how it might affect their blood pressure over 6 months. They will also find out the experiences of those doing this type of exercise and whether it can be done consistently at home over time.
Interventions
BEHAVIORALStandard care lifestyle advice
Healthy lifestyle advice for hypertension, given by a healthcare professional.
OTHERIsometric Exercise
Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
Sponsors
University of Kent
Canterbury Christ Church University
East Kent Hospitals University NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
Multi-centre randomized controlled feasibility study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 or over * Clinic systolic BP 140-159 mmHg * Able to provide informed consent
Exclusion criteria
* Currently taking anti-hypertensive medication * White coat hypertension, as evidenced by averaged home systolic BP \<135 mmHg * Inability to undertake study intervention (isometric exercise) * Previous history of any of the following: * Diabetes mellitus (Type 1 or type 2) * Ischaemic heart disease (myocardial infarction and/or coronary angina and/or coronary revascularization procedure) * Moderate or severe stenotic or regurgitant heart valve disease * Atrial or ventricular arrhythmia * Stroke or transient ischaemic attack * Aortic aneurysm and/or peripheral arterial disease * Uncorrected congenital or inherited heart condition * Estimated glomerular filtration rate \<45 ml/min (calculated using CKD-EPI or MDRD formulae, and taking most recent documented results) * Documented left ventricular ejection fraction \<45% and/or left ventricular hypertrophy (by either echocardiography or standard ECG criteria e.g. Sokolow-Lyon) * Documented urine albumin:creatinine ratio \>3.5 mg/mmol * Inability to provide informed consent * If female, pregnancy or currently breast feeding * Enrolled in another Clinical Trial of an Interventional Medicinal Product or Medical Device or other interventional study * Medical condition that, in the opinion of the investigator, would make the participant unsuitable for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Experience of intervention delivery | Project month 11 | Qualitative focus groups with health care professionals identifying the type and number of each barrier and facilitator, of the practical delivery of isometric exercise intervention. |
| Change in systolic blood pressure (mmHg) from baseline to Week 4. | Participant week 4 | — |
| Change in systolic blood pressure (mmHg) from baseline to Month 3. | Participant 3 months | — |
| Change in systolic blood pressure (mmHg) from baseline to Month 6. | Participant 6 months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in diastolic blood pressure (mmHg) from baseline to Week 4. | Week 4 | — |
| Change in diastolic blood pressure (mmHg) from baseline to Month 3. | Month 3 | — |
| Change in diastolic blood pressure (mmHg) from baseline to Month 6. | Month 6 | — |
| Early fidelity of the isometric exercise prescription. | Participant week 1 | Assessed by checking whether individual participant's heart rate (bpm) measures fall within 95% of their peak heart rate confidence intervals following the first three training sessions. |
| Short-term fidelity of the isometric exercise prescription. | Participant week 4 | Assessed by checking whether individual participant's heart rate (bpm) measures fall within 95% of their peak heart rate confidence intervals following the first four weeks (12) of training sessions. |
| Short-term adherence to the Isometric exercise (IE) training. | Participant week 4 | Measured using the proportion of participants (number) completing a minimum of 8 of 12 IE sessions up to the 4-week point. |
| Mid-term adherence to the Isometric exercise training. | Participant 3 Months | Measured using the proportion of participants (number) completing a minimum of two thirds of all IE sessions up to 3 months. |
| Long-term adherence to the Isometric exercise training. | Participant 6 Months | Measured using the proportion of participants (number) completing a minimum of two thirds of all IE sessions up to 6 months. |
| Recruitment rates from data collected at sites. | Project month 10 | This will be measured by calculating the average number of participants recruited per week. |
| Short-term attrition rates from data collected at sites. | Participant week 4 | This will be measured by calculating the number of withdrawals from the study up to 4 weeks. |
| Mid-term attrition rates from data collected at sites. | Participant 3 months | This will be measured by calculating the number of withdrawals from the study up to 3 months. |
| Long-term attrition rates from data collected at sites. | Participant 6 months | This will be measured by calculating the number of withdrawals from the study up to 6 months. |
| Experience of isometric exercise intervention. | Month 11 | Qualitative focus groups with study participants identifying the number of positive and negative experiences of the isometric exercise intervention and taking part in the study. |
| Participant experiences of undertaking isometric exercise. | Participant week 4. | Collected using participant study-specific survey with closed and open questions. |
| Subjective opinion of healthcare professionals on their willingness to consider the intervention as a treatment option for patients with Stage 1 hypertension. | Project month 11. | Collected using semi-structured interviews conducted by telephone with healthcare professionals from GP practices not taking part as study recruitment sites. |
| Short-term Quality-adjusted life years (QALYs) calculated from patients' responses to the EQ-5D-5L questionnaire. | Participant 4 weeks | The health profile established from EQ-5D-5L will be converted into a utility index (0 and 1) using the validated mapping function to derive utility values for EQ-5D-5L from the existing EQ-5D-3L. These utilities will be multiplied by the time spent in each state to generate QALYs. |
| Mid-term Quality-adjusted life years calculated from patients' responses to the EQ-5D-5L questionnaire. | Participant 3 months | The health profile established from EQ-5D-5L will be converted into a utility index (0 and 1) using the validated mapping function to derive utility values for EQ-5D-5L from the existing EQ-5D-3L. These utilities will be multiplied by the time spent in each state to generate QALYs. |
| Long-term Quality-adjusted life years calculated from patients' responses to the EQ-5D-5L questionnaire. | Participant 6 months | The health profile established from EQ-5D-5L will be converted into a utility index (0 and 1) using the validated mapping function to derive utility values for EQ-5D-5L from the existing EQ-5D-3L. These utilities will be multiplied by the time spent in each state to generate QALYs. |
| Healthcare resource utilisation (a). | Participant 4 weeks. | Measuring healthcare access by using the number of GP visits at 4 weeks. |
| Healthcare resource utilisation (b). | Participant 4 weeks. | Measuring healthcare access by using the number of nurse visits at 4 weeks. |
| Healthcare resource utilisation (c). | Participant 4 weeks. | Measuring healthcare access by using the number of other health professionals visits at 4 weeks. |
| Healthcare resource utilisation (d). | Participant 4 weeks. | Measuring healthcare access by using the number of number of A&E attendances at 4 weeks. |
| Healthcare resource utilisation (e). | Participant 4 weeks. | Measuring healthcare access by using the number of number of inpatient hospital admissions at 4 weeks. |
| Healthcare resource utilisation (f). | Participant 4 weeks. | Measuring healthcare access by using the number of inpatient diagnostic tests at 4 weeks. |
| Intervention costs. | Participant 4 weeks. | This will be measured by calculating the time cost of the training team and healthcare professionals, the cost of supplies and the equipment necessary to implement the intervention. |
| Intervention costs | Participant 6 months. | This will be measured by calculating the time cost of the training team and healthcare professionals, the cost of supplies and the equipment necessary to implement the intervention. |
| Medication at short-term time point (a) | Participant 4 weeks. | Measured using the frequency per week in days, start and end date per medication at 4 weeks. |
| Medication at mid-term time point (a) | Participant 3 months. | Measuring the frequency per week in days, start and end date per medication at 3 months. |
| Medication at long-term time point (a) | Participant 6 months. | Measuring the frequency per week in days, start and end date per medication at 6 months. |
| Medication at short-term time point (b) | Participant 4 weeks. | Measured using the dosage per day (mg), start and end date per medication at 4 weeks. |
| Medication at mid-term time point (b) | Participant 3 months. | Measuring the dosage per day (mg), start and end date per medication at 3 months. |
| Medication at long-term time point (b) | Participant 6 months. | Measuring the dosage per day (mg), start and end date per medication at 6 months. |
Countries
United Kingdom
Outcome results
None listed